Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 7/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23769467 | 0.86 | ITGAL (0.31) | — | |
| SCHEMBL23769456 | 0.83 | KLKB1 (0.33) | KLKB1 | |
| SCHEMBL23769708 | 0.81 | FAAH (0.35) | KLKB1KDM4E | |
| SCHEMBL23769465 | 0.77 | KLKB1 (0.42) | KLKB1KDM4EGRNSORT1 | |
| SCHEMBL23769711 | 0.76 | KLKB1 (0.38) | KLKB1KDM4E | |
| SCHEMBL23769707 | 0.72 | FAAH (0.34) | KLKB1KDM4E | |
| SCHEMBL23769569 | 0.71 | KLKB1 (0.35) | KLKB1KDM4E | |
| SCHEMBL23769563 | 0.69 | KLKB1 (0.33) | KLKB1 | |
| SCHEMBL23843164 | 0.67 | KLKB1 (0.37) | KLKB1KDM4E | |
| SCHEMBL21713091 | 0.65 | KLKB1 (0.36) | KLKB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-116120287-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| CN-116120287-A | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4103562-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| CN-115052873-A | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | 勃林格殷格翰国际有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885KDM4E 331/4885GRN 3987/4885 |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885KDM4E 331/4885GRN 3987/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885KDM4E 331/4885GRN 3987/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885KDM4E 331/4885GRN 3987/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885KDM4E 331/4885GRN 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.